Literature DB >> 22234802

Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.

Simona Coco1, Jessica Theissen, Paola Scaruffi, Sara Stigliani, Stefano Moretti, André Oberthuer, Francesca Valdora, Matthias Fischer, Fabio Gallo, Barbara Hero, Stefano Bonassi, Frank Berthold, Gian Paolo Tonini.   

Abstract

About 50% of children with neuroblastoma (NB) show a metastatic disease and have a poor prognosis. However, disease progression is greatly variable and depends on patients' age and MYCN oncogene amplification. To investigate the role of patients' age in tumor aggressiveness, we performed array-CGH and gene expression profiles of three groups (G) of metastatic NBs: G1, stage 4S patients and MYCN single copy (MYCN-) tumors; G2, stage 4 patients, ≤ 18 months of age, MYCN- tumors and favorable outcome and G3, Stage 4 patients, ≥ 19 months with unfavorable outcome. G1 was characterized by numerical aberrations prevalently; on the contrary, all G3 tumors had structural rearrangements, whereas G2 showed an intermediate pattern. The average of numerical alterations decreased significantly from G1 to G2 to G3 (p < 0.01). Contrarily, the number of structural aberrations increased from G1 to G2 to G3 (p < 2.35 E-05). Noteworthy, G3/MYCN- NBs were characterized by several complex intrachromosome rearrangements. Expression analysis of the three groups showed significant differences in genes of Rho and Ras signaling pathways, development and adhesion, cell cycle regulation and telomerase activity. Accumulation of structural alterations increased with patients' age and was associated with a more aggressive disease. Abnormal expression of genes involved in cell cycle and telomerase in G3 may be responsible for the genomic instability in this cohort of patients. The higher DNA instability observed in G3/MYCN- NBs than in MYCN-amplified G3 may also explain why patients ≥ 19 months have a poor outcome independently by MYCN status.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234802     DOI: 10.1002/ijc.27432

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.

Authors:  Simona Coco; Anna Truini; Angela Alama; Maria Giovanna Dal Bello; Roberta Venè; Anna Garuti; Enrico Carminati; Erika Rijavec; Carlo Genova; Giulia Barletta; Claudio Sini; Alberto Ballestrero; Francesco Boccardo; Francesco Grossi
Journal:  Target Oncol       Date:  2014-10-25       Impact factor: 4.493

2.  High genomic instability predicts survival in metastatic high-risk neuroblastoma.

Authors:  Sara Stigliani; Simona Coco; Stefano Moretti; Andrè Oberthuer; Mattias Fischer; Jessica Theissen; Fabio Gallo; Alberto Garavent; Frank Berthold; Stefano Bonassi; Gian Paolo Tonini; Paola Scaruffi
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

3.  Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Authors:  A P Berbegall; E Villamón; M Piqueras; I Tadeo; A Djos; P F Ambros; T Martinsson; I M Ambros; A Cañete; V Castel; S Navarro; R Noguera
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

4.  Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.

Authors:  Clare J Twist; Arlene Naranjo; Mary Lou Schmidt; Sheena C Tenney; Susan L Cohn; Holly J Meany; Peter Mattei; E Stanton Adkins; Hiroyuki Shimada; Wendy B London; Julie R Park; Katherine K Matthay; John M Maris
Journal:  J Clin Oncol       Date:  2018-11-16       Impact factor: 44.544

Review 5.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

6.  Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

Authors:  G Schleiermacher; V Mosseri; W B London; J M Maris; G M Brodeur; E Attiyeh; M Haber; J Khan; A Nakagawara; F Speleman; R Noguera; G P Tonini; M Fischer; I Ambros; T Monclair; K K Matthay; P Ambros; S L Cohn; A D J Pearson
Journal:  Br J Cancer       Date:  2012-09-13       Impact factor: 7.640

7.  Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm.

Authors:  Salvatore Masecchia; Simona Coco; Annalisa Barla; Alessandro Verri; Gian Paolo Tonini
Journal:  BMC Med Genomics       Date:  2015-09-10       Impact factor: 3.063

8.  Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.

Authors:  H Kocak; S Ackermann; B Hero; Y Kahlert; A Oberthuer; D Juraeva; F Roels; J Theissen; F Westermann; H Deubzer; V Ehemann; B Brors; M Odenthal; F Berthold; M Fischer
Journal:  Cell Death Dis       Date:  2013-04-11       Impact factor: 8.469

9.  Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Authors:  Eva Villamón; Ana P Berbegall; Marta Piqueras; Irene Tadeo; Victoria Castel; Anna Djos; Tommy Martinsson; Samuel Navarro; Rosa Noguera
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma.

Authors:  Giuliana Cangemi; Giorgio Reggiardo; Sebastiano Barco; Laura Barbagallo; Massimo Conte; Paolo D'Angelo; Maurizio Bianchi; Claudio Favre; Barbara Galleni; Giovanni Melioli; Riccardo Haupt; Alberto Garaventa; Maria V Corrias
Journal:  Onco Targets Ther       Date:  2012-11-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.